Latest News

The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.

A simple stool test may reveal hidden bowel disease in patients whose only symptoms are in their eyes.

Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina cases.

Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial results.

Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder of the neuromuscular junction that should be differentiated from myasthenia gravis, another neuromuscular junction disorder.

AREDS-based review links Mediterranean diet adherence to slower AMD and GA progression, as a complement to AREDS2 supplements.

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Arun C. Gulani, MD, applies his keratoconus classification to cross-linking, rings, transplant, lens surgery, and staged care.

Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.

Rheumatoid arthritis, is an autoimmune disorder, develops more often in women than men in a 3:1 ratio.

Sarah Cheng, MD, PhD, discusses findings on orbital tissue changes in thyroid eye disease after teprotumumab treatment.